Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
RNA interference (RNAi) is an evolutionarily conserved, endogenous process for post-transcriptional regulation of gene expression. Although RNAi therapeutics have recently progressed through the pipeline toward clinical trials, the application of these as ideal, clinical therapeutics requires the de...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/6/1/85 |
id |
doaj-abacb52a869445c0b16083d574fbbc35 |
---|---|
record_format |
Article |
spelling |
doaj-abacb52a869445c0b16083d574fbbc352020-11-25T03:51:37ZengMDPI AGPharmaceuticals1424-82472013-01-01618510710.3390/ph6010085Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and ChallengesJohn C. BurnettJohn J. RossiJiehua ZhouKa-To ShumRNA interference (RNAi) is an evolutionarily conserved, endogenous process for post-transcriptional regulation of gene expression. Although RNAi therapeutics have recently progressed through the pipeline toward clinical trials, the application of these as ideal, clinical therapeutics requires the development of safe and effective delivery systems. Inspired by the immense progress with nanotechnology in drug delivery, efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems. For example, a precisely engineered, multifunctional nanocarrier with combined passive and active targeting capabilities may address the delivery challenges for the widespread use of RNAi as a therapy. Therefore, in this review, we introduce the major hurdles in achieving efficient RNAi delivery and discuss the current advances in applying nanotechnology-based delivery systems to overcome the delivery hurdles of RNAi therapeutics. In particular, some representative examples of nanoparticle-based delivery formulations for targeted RNAi therapeutics are highlighted.http://www.mdpi.com/1424-8247/6/1/85small interfering (si)RNAnon-viral vectormultifunctional nanoparticletargeting deliverypassive and active targeting |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
John C. Burnett John J. Rossi Jiehua Zhou Ka-To Shum |
spellingShingle |
John C. Burnett John J. Rossi Jiehua Zhou Ka-To Shum Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges Pharmaceuticals small interfering (si)RNA non-viral vector multifunctional nanoparticle targeting delivery passive and active targeting |
author_facet |
John C. Burnett John J. Rossi Jiehua Zhou Ka-To Shum |
author_sort |
John C. Burnett |
title |
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges |
title_short |
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges |
title_full |
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges |
title_fullStr |
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges |
title_full_unstemmed |
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges |
title_sort |
nanoparticle-based delivery of rnai therapeutics: progress and challenges |
publisher |
MDPI AG |
series |
Pharmaceuticals |
issn |
1424-8247 |
publishDate |
2013-01-01 |
description |
RNA interference (RNAi) is an evolutionarily conserved, endogenous process for post-transcriptional regulation of gene expression. Although RNAi therapeutics have recently progressed through the pipeline toward clinical trials, the application of these as ideal, clinical therapeutics requires the development of safe and effective delivery systems. Inspired by the immense progress with nanotechnology in drug delivery, efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems. For example, a precisely engineered, multifunctional nanocarrier with combined passive and active targeting capabilities may address the delivery challenges for the widespread use of RNAi as a therapy. Therefore, in this review, we introduce the major hurdles in achieving efficient RNAi delivery and discuss the current advances in applying nanotechnology-based delivery systems to overcome the delivery hurdles of RNAi therapeutics. In particular, some representative examples of nanoparticle-based delivery formulations for targeted RNAi therapeutics are highlighted. |
topic |
small interfering (si)RNA non-viral vector multifunctional nanoparticle targeting delivery passive and active targeting |
url |
http://www.mdpi.com/1424-8247/6/1/85 |
work_keys_str_mv |
AT johncburnett nanoparticlebaseddeliveryofrnaitherapeuticsprogressandchallenges AT johnjrossi nanoparticlebaseddeliveryofrnaitherapeuticsprogressandchallenges AT jiehuazhou nanoparticlebaseddeliveryofrnaitherapeuticsprogressandchallenges AT katoshum nanoparticlebaseddeliveryofrnaitherapeuticsprogressandchallenges |
_version_ |
1724486535756120064 |